News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD®



10/4/2012 9:43:17 AM

NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS). Ex-RAD and other radioprotection strategies are increasingly important as the threat of accidental and intentional exposure to harmful radiation is becoming a major security concern. These new data were presented on October 3, 2012 at the 58th Annual Radiation Research Society Meeting in San Juan, Puerto Rico.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES